

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)



(10) International Publication Number
WO 2023/154282 A1

(51) International Patent Classification:

<i>C07D 401/04</i> (2006.01)	<i>C07D 519/00</i> (2006.01)
<i>C07D 401/14</i> (2006.01)	<i>A61K 31/4365</i> (2006.01)
<i>C07D 471/04</i> (2006.01)	<i>A61K 31/437</i> (2006.01)
<i>C07D 471/10</i> (2006.01)	<i>A61K 31/4375</i> (2006.01)
<i>C07D 487/04</i> (2006.01)	<i>A61K 31/472</i> (2006.01)
<i>C07D 495/04</i> (2006.01)	<i>A61K 31/4985</i> (2006.01)
<i>C07D 498/04</i> (2006.01)	<i>A61K 31/519</i> (2006.01)
<i>C07D 513/04</i> (2006.01)	<i>A61P 35/00</i> (2006.01)

(21) International Application Number:

PCT/US2023/012521

(22) International Filing Date:

07 February 2023 (07.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/307,882	08 February 2022 (08.02.2022)	US
63/416,772	17 October 2022 (17.10.2022)	US

(71) Applicants: **THERAS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, California 94304 (US). **LEIDOS BIOMEDICAL RESEARCH, INC.** [US/US]; P.O. Box B, 1050 Boyles Street, Frederick, Maryland 21702 (US). **LAWRENCE LIVERMORE NATIONAL SECURITY, LLC** [US/US]; 7000 East Avenue, P.O. Box 808, L-703, Livermore, California 94550 (US).

(72) Inventors: **XU, Rui**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **WANG, Bin**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **WALLACE, Eli**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **WEHN, Paul**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **BELTRAN, Pedro J.**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **STICE,**

James; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **SINKEVICIUS, Kerstin**; c/o BridgeBio Services, Inc., 3160 Porter Drive, Palo Alto, California 94304 (US). **YANG, Yue**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808 L-703, Livermore, California 94550 (US). **BISIGNANO, Paola**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808 L-703, Livermore, California 94550 (US). **LIGHTSTONE, Felice**; c/o Lawrence Livermore National Security, LLC, 7000 East Avenue, P.O. Box 808 L-703, Livermore, California 94550 (US). **SIMANSHU, Dharendra Kumar**; 3902 Sweet Briar Lane, Frederick, Maryland 21704 (US). **TURNER, David Michael**; 3320 Galena Drive, Apt. 101, Frederick, Maryland 21704 (US). **CZYZYK, Daniel J.**; 300 Cormorant Pl, #1220, Frederick, Maryland 21701 (US). **SINGH, Swapnil**; 5829 Broad Branch Way, Frederick, Maryland 21704 (US). **YERABOLU, Jayasudhan Reddy**; 812 Ivy Way, Apt #2B, Frederick, Maryland 21701 (US).


(74) Agent: **D'AMATO, Erica M.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

(54) Title: COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS

(57) Abstract: Provided herein are compounds and compositions thereof that may be capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.



(I)

WO 2023/154282 A1

[Continued on next page]

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*